Brought to you by 
Teijin gains Japanese rights to NeuroSigma's Monarch eTNS device for ADHD
22 Oct 2019
Executive Summary
NeuroSigma Inc. granted Teijin Pharma Ltd. exclusive Japanese marketing rights to its Monarch external trigeminal nerve stimulation (eTNS) system for the non-drug treatment of attention deficit hyperactivity disorder (ADHD). As part of the agreement, Teijin also gains patent rights in Japan to NeuroSigma's TNS technology in the ADHD indication.
Deal Industry
- Medical Devices
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teijin gains Japanese rights to NeuroSigma's Monarch eTNS device for ADHD
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice